<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127851</url>
  </required_header>
  <id_info>
    <org_study_id>TJO-018</org_study_id>
    <nct_id>NCT04127851</nct_id>
  </id_info>
  <brief_title>Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients</brief_title>
  <official_title>A Phase IV, Multicenter, Randomized, Single-blinded(Evaluator), Active-controlled, Parallel Study for Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Moderate to Severe Dry Eye Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taejoon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taejoon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with moderate to severe dry eye syndrome, the test drug (HA 0.15% eye drop) or
      the control drug (cyclosporin 0.05% eye drop) is administered for 12 weeks, and the corneal
      staining of each group would be evaluated. The study objective is to demonstrate that the
      test drug is not clinically inferior to the control drug.

      Furthermore, the efficacy of combination therapy would be evaluated through exploratory
      combination therapy group.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Corneal Staining Score at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>After 12 weeks of administration of the drugs compare the therapeutic effectiveness between control drug and trial drug evaluated as the corneal staining score change.
Scale: &quot;Oxford grading system&quot; that divides into six groups according to severity from 0 (absent) to 5 (severe).
The higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Corneal Staining Score at Week 4 and Week 8</measure>
    <time_frame>Baseline, Week 4 and Week 8</time_frame>
    <description>After 4, 8 weeks of administration of the drugs compare the therapeutic effectiveness between control drug and trial drug evaluated as the corneal staining score change.
Scale: &quot;Oxford grading system&quot; that divides into six groups according to severity from 0 (absent) to 5 (severe).
The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Dry Eye</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate 0.15%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporin 0.05%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJO-018</intervention_name>
    <description>TJO-018 / one drop / 6 times daily in both eyes</description>
    <arm_group_label>Sodium Hyaluronate 0.15%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Ophthalmic Emulsion 0.05%</intervention_name>
    <description>Cyclosporine / one drop / twice daily in both eyes</description>
    <arm_group_label>Cyclosporin 0.05%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJO-018 + Cyclosporine Ophthalmic Emulsion 0.05%</intervention_name>
    <description>TJO-018 one drop 6 times daily &amp; Cyclosporine one drop twice daily in both eyes</description>
    <arm_group_label>Combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 20 or over

          -  Moderate to Severe Dry Eye Disease Patients

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Any laser or ocular surgery within 2 months prior screening

          -  Use of contact lenses

          -  Any condition limiting patient's ability to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sukyoung Kwon, MPH., Candi. PhD</last_name>
    <phone>+82-799-0175</phone>
    <email>skkwon@taejoon.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taejoon Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

